Online citations, reference lists, and bibliographies.
← Back to Search

Cardiac Safety Of Adjuvant Pegylated Liposomal Doxorubicin With Concurrent Trastuzumab: A Randomized Phase II Trial.

D. Rayson, T. Suter, C. Jackisch, S. Van Der Vegt, B. Bermejo, J. van den Bosch, G. L. Vivanco, A. M. van Gent, H. Wildiers, A. Torres, L. Provencher, M. Temizkan, J. Chirgwin, J. Canon, G. Ferrandina, S. Srinivasan, L. Zhang, D. Richel
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND The cardiac safety of trastuzumab concurrent with pegylated liposomal doxorubicin (PLD) in an adjuvant breast cancer treatment regimen is unknown. PATIENTS AND METHODS Women with resected node-positive or intermediate-risk node-negative HER2 overexpressing breast cancer and baseline left ventricular ejection fraction (LVEF)≥55% were randomized (1:2) to doxorubicin 60 mg/m2 (A)+cyclophosphamide 600 mg/m2 (C) every 21 days (q21d) for four cycles or PLD 35 mg/m2+C q21d+trastuzumab 2 mg/kg weekly (H) for 12 weeks. Both groups then received paclitaxel (Taxol, T) 80 mg/m2 with H for 12 weeks followed by H to complete 1 year. The primary end point was cardiac event rate or inability to administer 1 year of trastuzumab. RESULTS Of 181 randomized patients, 179 underwent cardiac analysis. The incidence of cardiac toxicity or inability to administer trastuzumab due to cardiotoxicity was 18.6% [n=11; 95% confidence interval (CI) 9.7% to 30.9%] with A+C→T+H and 4.2% (n=5; 95% CI 1.4% to 9.5%) with PLD+C+H→T+H (P=0.0036). All events, except one, were asymptomatic systolic dysfunction or mildly symptomatic heart failure. Mean absolute LVEF reduction at cycle 8 was greater with doxorubicin (5.6% versus 2.1%; P=0.0014). CONCLUSION PLD+C+H→T+H is feasible and results in lower early cardiotoxicity rates compared with A+C→T+H.
This paper references
10.1056/NEJM200103153441101
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
10.1056/NEJMOA052122
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
E. H. Romond (2005)
10.1007/s10549-010-0838-7
Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group Trial E3198
A. Wolff (2010)
10.1093/annonc/mdr484
Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines.
D. M. Collins (2012)
10.1056/NEJMOA052306
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
M. Piccart-Gebhart (2005)
10.1016/S1470-2045(10)70006-1
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).
J. Bartlett (2010)
10.1093/annonc/mdn292
Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.
D. Rayson (2008)
10.1007/978-94-011-9562-1_10
In the Netherlands
H. V. Gelder (1961)
10.1200/JCO.2008.21.4577
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
H. Joensuu (2009)
10.1200/JCO.2005.03.8331
Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
S. Chia (2006)
10.1200/JCO.2009.26.0463
Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.
M. Procter (2010)
Dublin City University, Dublin; 2 Molecular Therapeutics for Cancer Ireland (MTCI) and UCD School of Medicine and Medical Science
Meeting highlights: international expert consensus on the primary treatment of early breast cancer
A Goldhirsch (2005)
Herceptin Package Insert Welwyn Garden City
Limited Roche Registration (2005)
10.1093/JNCI/90.18.1361
erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.
S. Paik (1998)
10.1200/JCO.2005.07.032
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
A. Buzdar (2005)
10.1023/A:1008216430806
The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin.
G. Berry (1998)
10.3816/CBC.2007.N.028
Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
E. Andreopoulou (2007)
10.1023/A:1008365716693
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.
T. Safra (2000)
10.1007/s10549-008-0306-9
Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial
E. Stickeler (2008)
Pegylated liposomal doxorubicin ( doxil ) : Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg / m 2
iT. Safra (2005)
Academic medical center.
Heyssel Rm (1985)
10.1056/NEJMOA054504
HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
K. Pritchard (2006)
10.1200/JCO.2009.22.7504
Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
M. Trudeau (2009)
10.1158/0008-5472.SABCS-09-80
Results of Chemotherapy Alone, with Sequential or Concurrent Addition of 52 Weeks of Trastuzumab in the NCCTG N9831 HER2-Positive Adjuvant Breast Cancer Trial.
E. Perez (2009)
10.1002/cncr.20207
Cardiac profiles of liposomal anthracyclines
M. Theodoulou (2004)
D M Collins
Hospital Provincial Hospital de Cruces Annals of Oncology
Antonio Anton Torres (2011)
10.1159/000207504
Trastuzumab Combined with Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer
C. Christodoulou (2009)
10.1200/JCO.2005.05.827
Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.
M. Ewer (2005)
10.1093/ANNONC/MDI326
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.
A. Goldhirsch (2005)
10.1093/JNCI/DJM252
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
A. Gennari (2008)
10.1093/ANNONC/MDH097
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
10.1093/JNCI/92.24.1991
HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15.
S. Paik (2000)
Dublin; 4 Molecular Therapeutics for Cancer Ireland (MTCI) and Department of Pathology and Laboratory Medicine, St. Vincent's University Hospital
(2011)
10.1158/0008-5472.SABCS-09-62
Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.
D. Slamon (2009)



This paper is referenced by
10.1158/1535-7163.MCT-15-0314
Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)
Elena Geretti (2015)
10.1002/cmdc.202000131
Antitumour Anthracyclines: Progress and Perspectives
M. Martins-Teixeira (2020)
10.1097/CAD.0000000000000182
Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes.
E. Tahover (2015)
Enhancing Cisplatin Delivery and Anti-tumor Efficacy Using Hyperthermia
Chelsea D. Landon (2013)
10.1159/000455823
Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief Overview
P. Menna (2017)
10.1016/j.clbc.2017.10.005
Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer
A. Chang (2018)
10.1007/s12609-012-0094-4
The Future of Chemotherapy in the Era of Personalized Medicine
Maria Vittoria Dieci (2012)
10.5041/RMMJ.10366
Surviving Cancer without a Broken Heart
O. Caspi (2019)
10.1007/s00280-017-3420-8
Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value
K. Skubitz (2017)
10.1111/bph.13643
Trastuzumab cardiotoxicity: from clinical trials to experimental studies
B. Németh (2017)
10.1007/s00280-019-03910-6
Current status of nanomedicine in the chemotherapy of breast cancer
A. I. Fraguas-Sánchez (2019)
10.1039/C2EM30640A
Potential environmental implications of nano-enabled medical applications: critical review.
Indrani Mahapatra (2013)
10.1177/1078155214531513
The role of anthracyclines in the treatment of early breast cancer
J. Greene (2015)
10.5301/tj.5000393
Trastuzumab Cardiac Toxicity: A Problem we Put our Heart Into
G. Bregni (2016)
10.1007/s11739-015-1362-x
Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer
S. Mantarro (2015)
10.1186/s12885-015-1433-4
Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study
K. Rau (2015)
10.1097/CRD.0000000000000194
Cardioprotection in the Modern Era of Cancer Chemotherapy
A. Godishala (2018)
10.2147/BCTT.S47227
Cardiac risk in the treatment of breast cancer: assessment and management
A. Valachis (2015)
10.1007/978-3-540-72314-1_9
Biotoxicity of Chemotherapy
C. Fung (2014)
10.1093/annonc/mdr534
Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.
X. He (2012)
10.1007/978-1-4939-2047-1_6
Targeted Therapies for HER2-positive Breast Cancer
M. V. Dieci (2015)
10.1007/s40259-013-0070-1
Pegylated Liposomal Doxorubicin: A Guide to Its Use in Various Malignancies
K. Lyseng-Williamson (2013)
10.1007/978-3-319-26012-9_50
Onco-Cardiology for Breast Cancer
O. Soran (2016)
10.1016/j.cct.2015.05.017
The use of unequal randomisation in clinical trials--An update.
E. Peckham (2015)
10.1155/2013/456409
Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A Review
J. Lao (2013)
10.1016/j.ccl.2019.08.001
Anthracycline Cardiotoxicity: It Is Possible to Teach an Old Dog Some New Tricks.
Jose Alvarez-Cardona (2019)
10.1016/j.drup.2016.10.003
New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.
Alberto A. Gabizon (2016)
10.1016/j.bbamem.2015.01.003
The concomitant management of cancer therapy and cardiac therapy.
E. Salvatorelli (2015)
10.1517/14740338.2016.1170115
Principles of a risk evaluation and mitigation strategy (REMS) for breast cancer patients receiving potentially cardiotoxic adjuvant treatments
Sherif Ahmed (2016)
Semantic Scholar Logo Some data provided by SemanticScholar